A review of economic impact of targeted oral anticancer medications

Chan Shen, Chun Ru Chien, Daniel M. Geynisman, Fabrice Smieliauskas, Ya Chen T Shih

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.

Original languageEnglish (US)
Pages (from-to)45-69
Number of pages25
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2014

Fingerprint

Economics
Costs and Cost Analysis
Information Storage and Retrieval
Pharmaceutical Preparations
Delivery of Health Care
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Health Policy

Cite this

Shen, Chan ; Chien, Chun Ru ; Geynisman, Daniel M. ; Smieliauskas, Fabrice ; Shih, Ya Chen T. / A review of economic impact of targeted oral anticancer medications. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2014 ; Vol. 14, No. 1. pp. 45-69.
@article{c0631f1a25bd4506ad22085fe7d524ef,
title = "A review of economic impact of targeted oral anticancer medications",
abstract = "There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.",
author = "Chan Shen and Chien, {Chun Ru} and Geynisman, {Daniel M.} and Fabrice Smieliauskas and Shih, {Ya Chen T}",
year = "2014",
month = "2",
day = "1",
doi = "10.1586/14737167.2014.868310",
language = "English (US)",
volume = "14",
pages = "45--69",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "1",

}

A review of economic impact of targeted oral anticancer medications. / Shen, Chan; Chien, Chun Ru; Geynisman, Daniel M.; Smieliauskas, Fabrice; Shih, Ya Chen T.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, No. 1, 01.02.2014, p. 45-69.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A review of economic impact of targeted oral anticancer medications

AU - Shen, Chan

AU - Chien, Chun Ru

AU - Geynisman, Daniel M.

AU - Smieliauskas, Fabrice

AU - Shih, Ya Chen T

PY - 2014/2/1

Y1 - 2014/2/1

N2 - There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.

AB - There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.

UR - http://www.scopus.com/inward/record.url?scp=84893044810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893044810&partnerID=8YFLogxK

U2 - 10.1586/14737167.2014.868310

DO - 10.1586/14737167.2014.868310

M3 - Review article

C2 - 24378038

AN - SCOPUS:84893044810

VL - 14

SP - 45

EP - 69

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -